Safety Reading Notes

Read safety context beside the research guide.

The Anandamide source set includes safety-context rows around anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms. Public reading should keep these rows beside the benefit-oriented buckets, because product identity, dose, route, population, impairment, interactions, and adverse-event context can change what a study means. PMID 36150527

Mechanistic research summary: insufficient (11), mechanistic or pharmacological (4)

PubMed For Dummies Article

Anandamide Evidence Review: the long-form source walk-through

Quick read
  • Anandamide currently has 20 source-backed evidence row(s), so this page should be read as a research guide rather than a single conclusion. PMID 36150527
  • The evidence classes most visible in the row language are insufficient (16), and mechanistic or pharmacological (4). PMID 16678907
  • The study-design language most visible in the row language is Narrative or expert review (16), Cellular or in vitro study (2), and Animal study (2). PMID 16596776
  • The repeated topics are anandamide biology, receptor pharmacology, metabolism, physiology, or safety-... (15), CB2 (2), GPR119 (2), and TRPV1 (1), which tells the reader where to start opening PubMed and DOI links. PMID 19413995

Start with the research question

Anandamide is built from 20 source-backed evidence row(s) and 20 research source(s). The current evidence classes read as insufficient (16), and mechanistic or pharmacological (4), and the study-design language most often reads as Narrative or expert review (16), Cellular or in vitro study (2), and Animal study (2). PMID 36150527

The row-level question is not simply whether Anandamide is "good" or "bad." The useful question is what each row studied, what evidence class it received, and whether the source is close to the reader's actual question. The most repeated row topics are anandamide biology, receptor pharmacology, metabolism, physiology, or safety-... (15), CB2 (2), GPR119 (2), and TRPV1 (1). PMID 16678907

Human evidence 0 rows

Rows involving human participants, patients, or clinical source language. These rows are closer to everyday reader questions, but still depend on population, dose, route, comparator, and endpoint. PMID 20353771

Preclinical evidence 0 rows

Animal, cellular, or model-based rows. These can explain why a topic is being studied, but they should not be read as human-health instructions. PMID 26411767

Mechanistic evidence 4 rows

Rows about receptors, enzymes, channels, metabolism, binding, signaling, or pharmacology. These explain plausibility without proving a consumer outcome. PMID 27516570

Limits and uncertainty 16 rows

Rows where safety, tolerability, risk, product limits, or insufficient evidence need to stay visible next to the rest of the article. PMID 22297258

The lane labels are not a quality score. They are a reading method: keep human evidence, preclinical evidence, mechanisms, and uncertainty in separate mental boxes before deciding what a source can actually support. PMID 12052051

Where this page has the most source density

The largest bucket surfaced for this page is anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms. That does not automatically mean the topic is settled; it means this is where the current source trail is densest. The next visible bucket is CB2, which gives readers another way to see what the literature repeatedly circles. PMID 36150527

Source density should be read with evidence posture. A bucket can contain many rows and still be limited if the studies are indirect, mixed, preclinical, product-specific, or mostly review-level. The paragraphs below name the buckets directly and keep each explanation connected to a source record. PMID 16678907

Bucket chapters: what the literature is circling

anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms

15 research sources 15 rows (1063-1077) Mechanistic research summary: insufficient (11), mechanistic or pharmacological (4)

Anandamide appears in rows studying anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms. It currently draws from 15 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 36150527

Read this bucket as safety context first. It belongs beside any benefit-oriented rows because risk, route, dose, product quality, co-exposures, and population can change what a source means. PMID 36150527

  • Evidence row 1063

    Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: anandamide biolog... PMID 36150527

  • Evidence row 1077

    Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: anandamide biolog... PMID 24325918

CB2

2 research sources 2 rows (890-894) Mapped evidence with interpretation limits: insufficient (2)

Anandamide appears in rows about CB2 mechanisms. It currently draws from 2 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 16678907

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 16678907

  • Evidence row 890

    Anandamide modulates CB2; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signalin... PMID 16678907

  • Evidence row 894

    Anandamide modulates CB2; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 16596776

GPR119

2 research sources 2 rows (964-965) Mapped evidence with interpretation limits: insufficient (2)

Anandamide appears in rows about GPR119 mechanisms. It currently draws from 2 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 19413995

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 19413995

  • Evidence row 964

    Anandamide modulates GPR119; evidence class: insufficient (study design: Narrative or expert review; outcome measure: GPR119 receptor activity, binding, signaling, metabolic physiology, or pharmacology). PMID 19413995

  • Evidence row 965

    Anandamide modulates GPR119; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: GPR119 receptor activity, binding, signaling, metabolic physiolo... PMID 20353771

TRPV1

1 research source 979 Mapped evidence with interpretation limits: insufficient (1)

Anandamide appears in rows about TRPV1 mechanisms. It currently draws from 1 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 26411767

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 26411767

  • Evidence row 979

    Anandamide modulates TRPV1; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, bindin... PMID 26411767

Human evidence, mechanisms, and safety are different lanes

This page currently separates human evidence (0 row(s)), mechanistic evidence (4 row(s)), and safety/tolerability context (0 row(s)). That separation is the heart of the site. Mechanistic evidence can make a topic biologically interesting, but it should not silently become a human outcome. PMID 36150527

Human evidence still depends on population, dose, route, duration, product identity, and endpoint. Safety rows belong in the same reading path as benefit-oriented rows because formulation, co-exposures, prescription medications, impairment context, and higher-risk populations can change how close a source is to a reader's question. PMID 16678907

What this does and does not mean

  • It means the page has a traceable source trail. It does not mean every bucket has the same clinical strength. PMID 34126378
  • It means mechanisms, animal models, human studies, safety rows, and insufficient-evidence rows are being kept visible as separate evidence types. PMID 25461979
  • It does not turn a preclinical mechanism into a consumer recommendation, and it does not treat one product, dose, route, or population as interchangeable with another. PMID 20302856

How to use the source table

The source-backed evidence table below is the audit trail. Each row keeps a public sentence connected to a source record when a PubMed ID or DOI is available. If a sentence feels important, the reader should be able to click through, inspect the study type, and decide whether the source is close to the question they care about. PMID 36150527

This is why the public page is intentionally layered. The top gives the reader a fast orientation. The bucket table groups repeated rows into readable topics. The article body explains the buckets using the actual evidence-row language. The source notes below walk through every evidence row before the source table repeats the technical trace. PMID 16678907

Source-reading checklist for Anandamide

  1. Open the linked PubMed or DOI record. PMID 27100705
  2. Check whether the source studied humans, animals, cells, chemistry, pharmacology, product testing, or a review of prior literature. PMID 35038882
  3. Compare the source product, dose, route, population, and endpoint to the question being asked. PMID 35986066
  4. Look for safety, tolerability, drug-interaction, impairment, pregnancy, pediatric, psychiatric, cardiovascular, and product-quality context before treating the bucket as settled. PMID 11470906
  5. Return to the evidence table when the article summary sounds too broad; the row is the audit unit. PMID 32867595

Source Notes

Anandamide source-by-source reading notes

These notes pull every evidence row on this page into the readable article body before the source table repeats the audit trail. Each note keeps the row language beside the PubMed or DOI link when available.

  1. Evidence row 890

    Anandamide modulates CB2; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 16678907

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Biochemistry, pharmacology and physiology of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand.
  2. Evidence row 894

    Anandamide modulates CB2; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 16596776

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Structural requirements for cannabinoid receptor probes.
  3. Evidence row 964

    Anandamide modulates GPR119; evidence class: insufficient (study design: Narrative or expert review; outcome measure: GPR119 receptor activity, binding, signaling, metabolic physiology, or pharmacology). PMID 19413995

    Evidence class: insufficient; Study design: Narrative or expert review. Source: N-acylethanolamines, anandamide and food intake.
  4. Evidence row 965

    Anandamide modulates GPR119; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: GPR119 receptor activity, binding, signaling, metabolic physiology, or pharmacology). PMID 20353771

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Palmitoylethanolamide and other anandamide congeners. Proposed role in the diseased brain.
  5. Evidence row 979

    Anandamide modulates TRPV1; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 26411767

    Evidence class: insufficient; Study design: Narrative or expert review. Source: TRPV1 Channel: A Potential Drug Target for Treating Epilepsy.
  6. Evidence row 1063

    Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 36150527

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Anandamide and other N-acylethanolamines: A class of signaling lipids with therapeutic opportunities.
  7. Evidence row 1064

    Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 27516570

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Metabolism of endocannabinoids.
  8. Evidence row 1065

    Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 22297258

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Anandamide uptake explained?
  9. Evidence row 1066

    Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 12052051

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Anandamide receptors.
  10. Evidence row 1067

    Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 34126378

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: The major endocannabinoid anandamide (AEA) induces apoptosis of human granulosa cells.
  11. Evidence row 1068

    Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 25461979

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Endocannabinoid metabolism by cytochrome P450 monooxygenases.
  12. Evidence row 1069

    Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Narrative or expert review; outcome measure: anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 20302856

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Endocannabinoids and pregnancy.
  13. Evidence row 1070

    Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 27100705

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Anandamide and its metabolites: what are their roles in the kidney?
  14. Evidence row 1071

    Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 35038882

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Endocannabinoids.
  15. Evidence row 1072

    Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 35986066

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabinoid CB1 receptors regulate salivation.
  16. Evidence row 1073

    Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 11470906

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase.
  17. Evidence row 1074

    Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 32867595

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Targeting Endocannabinoid Signaling: FAAH and MAG Lipase Inhibitors.
  18. Evidence row 1075

    Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 32894511

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Druggable Targets in Endocannabinoid Signaling.
  19. Evidence row 1076

    Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 23512546

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Chemical probes of endocannabinoid metabolism.
  20. Evidence row 1077

    Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 24325918

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Amygdala FAAH and anandamide: mediating protection and recovery from stress.